Germans are wondering whether the cuts in were inspired, at least in part, by the government's new austerity plans for drug spending -- something Pfizer is hinting at. Pfizer's pain drug Lyrica is expected to face a price cap, for instance, and new drugs will have to prove themselves better than existing treatments during their first year on the market or face government-imposed prices. As a Pfizer spokesman said, as quoted by The Local, "The health care policy environment has clearly clouded the expectations for future business."
via fool.com
No comments:
Post a Comment